Skip to content
Back to meeting Original
ESMO - Eur. Oncology· @myESMO · X·· 2 days agoScore70

MOIO

Body

#ESMO26: Data from the MOIO trial were inconclusive regarding whether de-escalating #immunotherapy is beneficial after previous response to 6-month #ImmuneCheckpointInhibitor therapy in patients with a range of advanced #SolidTumours.
#InsightsbyESMO ➡️https://ow.ly/9WhK51002S2

26 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: ESMO - Eur. Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.